Stirling cranks up Canada plant with tablet job

Australia's Stirling Products is up and running at its Canadian drug-making facility, purchased about a year ago "at a major discount" to its assessed value of $20 million. The 4,270-square-meter Cape Breton, Nova Scotia, plant is currently producing 300 kilograms of tableted product on its first contract.

The bargain purchase of the operating plant followed the collapse of an unnamed Canadian pharmaceutical group and its institutional lender. Stirling nonetheless had to revalidate all plant and equipment as well as processes and procedures to gain manufacturing permits from Canadian authorities.

The drugmaker expects to begin manufacturing this month using on-hand acetaminophen stock. The plant is built for the manufacture and packaging of 550 million tablets and 5 million bottles. Blend capacity is 1.5 million kilograms. It marks a milestone in Stirling's global positioning strategy.

- here's the story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.